Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin In Dravet Syndrome; First Sites Activated With A Number Of Additional Rapid-Start Sites Being Activated In The Coming Weeks
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin In Dravet Syndrome; First Sites Activated With A Number Of Additional Rapid-Start Sites Being Activated In The Coming Weeks
Longboard Pharmaceuticals启动第3期深海研究，评估Bexicaserin在Dravet综合症中的作用；首批研究点已经激活，未来几周将会有更多快速启动点激活。
- First sites activated with a number of additional rapid-start sites being activated in the coming weeks
- 首批站点已启动，并将在未来几周启动更多快速启动站点
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational drugbexicaserin for the treatment of seizures associated with Dravet syndrome in participants two years of age and older.
Longboard Pharmaceuticals, Inc.（纳斯达克:LBPH），一家临床阶段的生物制药公司，致力于开发用于治疗神经系统疾病的新型、变革性药物，今天宣布已开始进行全球第三阶段DEEp SEA研究，评估其研究药物bexicaserin用于治疗特拉维特（Dravet）综合征患者中两岁及以上参与者的癫痫。